Low blood sodium is a common observation in patients presenting with heart failure and is
associated with increased mortality, prolonged hospital stay, and repeat hospital visits.
Tolvaptan is a new and approved medication to treat low sodium levels in patients who present
with symptoms of heart failure, however, it is not currently available as a treatment option
due to high costs not covered by our provincial plan. In this observational, non-randomized
study the drug will be provided to all subjects free of charge and given only during their
hospital stay. After discharge subjects will be followed for 6 months (3 visits).